Table 2. Subgroup analyses of studies included in meta-analysis.
| Factors | Subgroups | Number of included studies | Crude OR(95%CI) | Statistical model | I2 | Pheterogeneity |
|---|---|---|---|---|---|---|
| Study design | Case-control study | 3 | 1.72(1.03–2.89) | Fixed | 4.1% | 0.352 |
| Cohort study | 13 | 1.63(1.38–1.93) | Fixed | 34.3% | 0.108 | |
| Sources of infection | Bacteraemia | 10 | 1.54(1.23–1.93) | Fixed | 11.6% | 0.336 |
| Any infection or colonization | 6 | 1.92(1.31-2.81) | Random | 47.7% | 0.089 | |
| Region | Europe | 3 | 1.55(1.10–2.18) | Fixed | 0.0% | 0.454 |
| Asia | 5 | 1.82(1.06–3.11) | Random | 57.8% | 0.05 | |
| North America | 6 | 1.82(1.44–2.29) | Fixed | 1.8% | 0.405 | |
| South America | 2 | 1.12(0.64–1.99) | Fixed | 43.5% | 0.183 | |
| Type of carbapenem | Carbapenem | 8 | 1.30(1.02–1.67) | Fixed | 0.0% | 0.698 |
| Meropenem | 1 | 2.51(1.20–5.26) | Fixed | NA | NA | |
| Imipenem | 7 | 1.92(1.54–2.39) | Fixed | 35.0% | 0.161 |
Abbreviations: NA, not available.